Pro-chemotherapeutic effects of antibody against extracellular domain of claudin-4 in bladder cancer

Cancer Letters
Masaomi KuwadaHiroki Kuniyasu

Abstract

Bladder cancer displays an aggressive phenotype in the muscle-invasive phase, and is associated with a high mortality rate. Therefore, novel molecular therapeutic targets are needed to improve patient survival. A monoclonal antibody against the extracellular domain of the claudin-4 (CLDN4) tight junction protein was established by immunizing rats with a plasmid vector encoding human CLDN4. A hybridoma clone, producing a rat monoclonal antibody recognizing CLDN4 (clone 4D3), was obtained. Immunohistochemistry by using the 4D3 antibody showed that CLDN4 expression was associated with local invasion, nodal metastasis, distant metastasis, and advanced stage in 86 cases of bladder cancer. The 4D3 antibody inhibited growth, invasion, and survival, associated with abrogation of the intratumoral microenvironment; lowered concentrations of epidermal growth factor and vascular endothelial growth factor were found in three-dimensional cultures of T24 and RT4 cells. In combination with cisplatin therapy, 4D3 enhanced cisplatin cytotoxicity by increasing cellular permeability, leading to increased intracellular cisplatin concentrations. In mouse models of subcutaneous tumors and lung metastasis, 4D3 enhanced tumor growth inhibition, alone a...Continue Reading

References

Apr 29, 1998·Annual Review of Physiology·L L Mitic, J M Anderson
Nov 14, 2000·The American Journal of Pathology·H KuniyasuI J Fidler
Apr 3, 2001·Nature Reviews. Molecular Cell Biology·S TsukitaM Itoh
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Dec 21, 2004·Expert Review of Anticancer Therapy·Judi C Herring, Ashish M Kamat
Mar 4, 2005·The American Journal of Pathology·Hiroki KuniyasuHitoshi Ohmori
Dec 7, 2006·Nature Clinical Practice. Urology·Kokichi Sugano, Tadao Kakizoe
Apr 17, 2008·Histochemistry and Cell Biology·Carola Förster
Sep 5, 2008·Nature Clinical Practice. Urology·Mohamed A Ghoneim, Hassan Abol-Enein
Jan 13, 2010·Cold Spring Harbor Perspectives in Biology·James M Anderson, Christina M Van Itallie
Jan 26, 2010·Biochemical Pharmacology·Hiroshi UchidaKiyohito Yagi
Feb 25, 2010·Annals of Surgical Oncology·Stephen B Edge, Carolyn C Compton
May 6, 2010·The Journal of Pharmacology and Experimental Therapeutics·Rie SaekiKiyohito Yagi
Jan 5, 2011·Frontiers in Bioscience (Landmark Edition)·Astrid Escudero-EsparzaTracey A Martin
Apr 7, 2011·Current Medicinal Chemistry·A TakahashiK Yagi
Apr 26, 2011·Biochimica Et Biophysica Acta·Kursad Turksen, Tammy-Claire Troy
Aug 17, 2011·Laboratory Investigation; a Journal of Technical Methods and Pathology·Mi Jeong KwonYoung Kee Shin
Jan 31, 2012·Archives of Biochemistry and Biophysics·A NeesseP Michl
Jun 5, 2012·Biochemical and Biophysical Research Communications·Koji MatsuhisaKiyohito Yagi
Jul 18, 2012·Expert Opinion on Therapeutic Targets·Takashi KojimaNorimasa Sawada
Oct 26, 2012·Neoplasia : an International Journal for Oncology Research·Xiying ShangStephen B Howell
Apr 9, 2013·International Journal of Oncology·S M HashimiM Q Wei
Nov 16, 2013·Cancer Management and Research·Lei DingYan-Hua Chen
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Jul 21, 2014·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Dinç SürenCem Sezer
Aug 15, 2014·The Journal of Pharmacology and Experimental Therapeutics·Xiangru LiMasuo Kondoh

❮ Previous
Next ❯

Citations

Aug 16, 2016·Biochemical and Biophysical Research Communications·Theodore G GabigVictor Romanov
Aug 16, 2016·Oncogene·S Tabariès, P M Siegel
Apr 6, 2017·BMC Complementary and Alternative Medicine·Lili TianGuofu Zhu
Aug 27, 2017·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Julia Baguña TorresBart Cornelissen
Sep 21, 2017·The Journal of Pharmacology and Experimental Therapeutics·Mutsumi TakigawaMasuo Kondoh
Dec 12, 2018·The Journal of Pharmacology and Experimental Therapeutics·Yosuke HashimotoMasuo Kondoh
Sep 10, 2019·Cancer Medicine·Takamitsu SasakiHiroki Kuniyasu
May 2, 2019·Oncotarget·Yukiko NishiguchiHiroki Kuniyasu
Jun 3, 2020·International Journal of Molecular Sciences·Rina Fujiwara-TaniHiroki Kuniyasu
Feb 23, 2020·Cancer Science·Yi LuoHiroki Kuniyasu
Dec 22, 2019·International Journal of Molecular Sciences·Saiprasad GowrikumarPunita Dhawan
Apr 18, 2017·Annals of the New York Academy of Sciences·Yosuke HashimotoMasuo Kondoh
Jun 4, 2020·International Journal of Molecular Sciences·Takamitsu SasakiHiroki Kuniyasu
Nov 12, 2020·International Journal of Molecular Sciences·Takuya OwariHiroki Kuniyasu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis